Week in Review: Unnamed Entity Raises Chindex Bid to $23

Chindex, which operates private hospitals and clinics in China, received an 18% higher takeover offer of $23 per share from an undisclosed entity; Guangxi Wuzhou Zhongheng will establish a pharma M&A fund with partners for up to $162 million; Changchun BCHT Biotech received China rights to a RSV vaccine from Mucosis, a Dutch vaccine company, after contributing to Mucosis' $6.9 million fundraising; Techne will acquire Shanghai PrimeGene Bio-Tech, which makes recombinant proteins; Dr. Steve Yang joined WuXi PharmaTech as COO and Vice-President; Johnson & Johnson broke ground on a $300 million facility in the Xi'an High-tech Development Zone; Zhejiang Hisun Pharma bought biosimilar cell lines from Catalent Pharma of the US; and China will remove price limits on some Essential Drug List products, promising pharmas reasonable profits in return for improved supply. More details…. Stock Symbols: (NSDQ: CHDX) (SHA: 600252) (NSDQ: TECH) (NYSE: WX) (NYSE: JNJ) (SHA: 600267) Share this with colleagues: // //